Category: Other
Objective: To present the impact on cognition, quality of life, and non-motor symptoms after 1-year of DBS for Parkinson’s Disease through the ADROIT post-market study.
Background: DBS improves motor outcomes and quality of life (QoL) in patients with movement disorders, including Parkinson’s disease (PD). However, complications have been reported with DBS for PD, including decline in specific cognitive subdomains. As Parkinson’s progresses, non-motor symptoms have a greater impact on QoL. We report the impact of a modern directional DBS system on cognition, non-motor symptoms, and QoL in patients with DBS for PD.
Method: ADROIT is a large, international, prospective, post-market, observational study at up to 50 centers worldwide that collects long-term safety and effectiveness data on Abbott DBS systems in the real-world setting. The NAPA sub-study will evaluate non-motor and cognitive changes after DBS with a modern directional DBS system.
Results: As of February 2022, a total of 202 PD patients have received newly implanted DBS systems in ADROIT across 28 sites. MoCA scores have been reported for 150 patients at baseline, with an average score of 25.4 ± 3.3, and for 23 patients at 1-year, with an average score of 25.0 ± 4.4. MoCA scores for patients changed from 25.7 ± 3.7 to 25.3 ± 4.2 among 18 patients with available paired data. MDS-UPDRS Part I scores were reported for 169 patients at baseline with an average score of 11.2 ± 5.5. At 6-months, 78 patients reported an average score of 17.0 ± 7.4. Part I scores changed from 9.9 ± 5.5 to 8.5 ± 5.4 among 73 patients with available paired data.
Conclusion: This interim report will investigate the impact of Directional DBS systems on cognition, QoL, and non-motor symptoms by summarizing available 1-year paired data for non-motor assessments, providing the first large scale evaluation of the effect of modern DBS systems.
To cite this abstract in AMA style:
M. Poetter-Nerger, S. Groppa, O. Adam, A. Schnitzler, M. Navas Garcia, B. Cheeran, L. Himes, M. Frassica, A. Gharabaghi. Impact on non-motor symptoms, cognition, and QoL after 1-year of DBS for Parkinson’s Disease: An interim report from the ADROIT NAPA sub-study [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/impact-on-non-motor-symptoms-cognition-and-qol-after-1-year-of-dbs-for-parkinsons-disease-an-interim-report-from-the-adroit-napa-sub-study/. Accessed June 15, 2025.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/impact-on-non-motor-symptoms-cognition-and-qol-after-1-year-of-dbs-for-parkinsons-disease-an-interim-report-from-the-adroit-napa-sub-study/